83 related articles for article (PubMed ID: 15233669)
1. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial.
Pockros PJ; Carithers R; Desmond P; Dhumeaux D; Fried MW; Marcellin P; Shiffman ML; Minuk G; Reddy KR; Reindollar RW; Lin A; Brunda MJ;
Am J Gastroenterol; 2004 Jul; 99(7):1298-305. PubMed ID: 15233669
[TBL] [Abstract][Full Text] [Related]
2. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study.
Bruno R; Sacchi P; Ciappina V; Zochetti C; Patruno S; Maiocchi L; Filice G
Antivir Ther; 2004 Aug; 9(4):491-7. PubMed ID: 15456079
[TBL] [Abstract][Full Text] [Related]
3. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
4. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.
Perry CM; Jarvis B
Drugs; 2001; 61(15):2263-88. PubMed ID: 11772139
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
Heathcote EJ; Shiffman ML; Cooksley WG; Dusheiko GM; Lee SS; Balart L; Reindollar R; Reddy RK; Wright TL; Lin A; Hoffman J; De Pamphilis J
N Engl J Med; 2000 Dec; 343(23):1673-80. PubMed ID: 11106716
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.
Reddy KR; Wright TL; Pockros PJ; Shiffman M; Everson G; Reindollar R; Fried MW; Purdum PP; Jensen D; Smith C; Lee WM; Boyer TD; Lin A; Pedder S; DePamphilis J
Hepatology; 2001 Feb; 33(2):433-8. PubMed ID: 11172346
[TBL] [Abstract][Full Text] [Related]
7. Peginterferon alfa-2a (40KD) (Pegasys) for the treatment of patients with chronic hepatitis C.
Ferenci P
Int J Clin Pract; 2003 Sep; 57(7):610-5. PubMed ID: 14529063
[TBL] [Abstract][Full Text] [Related]
8. Peginterferon alfa-2a in patients with chronic hepatitis C.
Zeuzem S; Feinman SV; Rasenack J; Heathcote EJ; Lai MY; Gane E; O'Grady J; Reichen J; Diago M; Lin A; Hoffman J; Brunda MJ
N Engl J Med; 2000 Dec; 343(23):1666-72. PubMed ID: 11106715
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
[TBL] [Abstract][Full Text] [Related]
10. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.
Hassanein T; Cooksley G; Sulkowski M; Smith C; Marinos G; Lai MY; Pastore G; Trejo-Estrada R; Horta E Vale A; Wintfeld N; Green J
J Hepatol; 2004 Apr; 40(4):675-81. PubMed ID: 15030985
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
[TBL] [Abstract][Full Text] [Related]
12. Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a.
Marcellin P; Lau GK; Zeuzem S; Heathcote EJ; Pockros PJ; Reddy KR; Piratvisuth T; Farci P; Chow WC; Jia JD; Paik W; Wintfeld N; Pluck N
Liver Int; 2008 Apr; 28(4):477-85. PubMed ID: 18339074
[TBL] [Abstract][Full Text] [Related]
13. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study.
Liu CH; Liang CC; Lin JW; Chen SI; Tsai HB; Chang CS; Hung PH; Kao JH; Liu CJ; Lai MY; Chen JH; Chen PJ; Kao JH; Chen DS
Gut; 2008 Apr; 57(4):525-30. PubMed ID: 17881538
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.
Lindsay KL; Trepo C; Heintges T; Shiffman ML; Gordon SC; Hoefs JC; Schiff ER; Goodman ZD; Laughlin M; Yao R; Albrecht JK;
Hepatology; 2001 Aug; 34(2):395-403. PubMed ID: 11481625
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients.
Diago M; Crespo J; Olveira A; Pérez R; Bárcena R; Sánchez-Tapias JM; Muñoz-Sánchez M; Romero-Gómez M
Aliment Pharmacol Ther; 2007 Oct; 26(8):1131-8. PubMed ID: 17894655
[TBL] [Abstract][Full Text] [Related]
16. Pegylated interferon monotherapy for chronic hepatitis C.
Heathcote J; Zeuzem S
Semin Liver Dis; 2004; 24 Suppl 2():39-45. PubMed ID: 15346245
[TBL] [Abstract][Full Text] [Related]
17. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A;
J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
[TBL] [Abstract][Full Text] [Related]
19. Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.
Hasan F; Al-Khaldi J; Asker H; Al-Ajmi M; Owayed S; Varghese R; Siddique I; Al-Nakib B
Antivir Ther; 2004 Aug; 9(4):499-503. PubMed ID: 15456080
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4.
Alfaleh FZ; Hadad Q; Khuroo MS; Aljumah A; Algamedi A; Alashgar H; Al-Ahdal MN; Mayet I; Khan MQ; Kessie G
Liver Int; 2004 Dec; 24(6):568-74. PubMed ID: 15566506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]